Biotech catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
Windows longer than 90 days are part of TrialScanner, so this list covers the next 90 days.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 30, 2026Sponsor estimate | NCT05689372Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type...Novo Nordisk A/S · Diabetes Mellitus, Type 2 | NVOLead | No phase registered | Enrolling by invitation | Locked | Locked | Locked |
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT05689372Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type...Novo Nordisk A/S · Diabetes Mellitus, Type 2Enrolling by invitationNVOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 2026Sponsor estimateNo phase registeredNCT03404778Comprehensive Reverse Shoulder Data CollectionZimmer Biomet · Arthropathy of Shoulder RegionEnrolling by invitationZBHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 3NCT03683186A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionUnited Therapeutics · PAHEnrolling by invitationUTHRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT06443463Long-term Safety and Tolerability of BHV-7000Biohaven Therapeutics Ltd. · Focal EpilepsyEnrolling by invitationBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 3NCT07832552A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and...Harrow Inc · Postoperative Ocular InflammationEnrolling by invitationHROWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimateNo phase registeredNCT07910422Intradiscal Ozone/Oxygen Injection for Treatment of Contained Lumbar Disc HerniationBeam Research, Inc. · Lumbar Disc HerniationEnrolling by invitationBEAMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimateNo phase registeredNCT04682145Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa PegolNovo Nordisk A/S · Haemophilia AEnrolling by invitationNVOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 26, 2026Sponsor estimateNo phase registeredNCT07653139Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in GermanyNovo Nordisk A/S · Haemophilia AEnrolling by invitationNVOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 3NCT05303532Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With DurvalumabAstraZeneca · CancerEnrolling by invitationAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1/Phase 2NCT06138743Study of SRP-1003 in Participants With Type 1 Myotonic DystrophySarepta Therapeutics, Inc. · Myotonic Dystrophy 1Enrolling by invitationSRPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT06453187A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg UlcersIntegra LifeSciences Corporation · Diabetic Foot UlcerEnrolling by invitationIARTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT07443202Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)Tarsus Pharmaceuticals, Inc. · Ocular RosaceaEnrolling by invitationTARSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT07623564Clinical Study on Tissue Preservation in Breast Augmentation and ReconstructionEstablishment Labs · Breast Augmentation and Breast ReconstructionEnrolling by invitationESTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT07713901Database Linkage Study to Evaluate the Risk of Medullary Thyroid CarcinomaNovo Nordisk A/S · Medullary Thyroid CarcinomaEnrolling by invitationNVOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 2027Sponsor estimate | NCT06595615Health App Data Collection StudyAbbott Medical Devices · Cardiac Disease | ABTLead | No phase registered | Enrolling by invitation | Locked | Locked | Locked |
| Jan 2027Sponsor estimate | NCT06873035An Interventional Study of Infigratinib in Children With HypochondroplasiaQED Therapeutics, a BridgeBio company · Hypochondroplasia | BBIOLead | Phase 2/Phase 3 | Enrolling by invitation | Locked | Locked | Locked |
- Primary completion Jan 2027Sponsor estimateNo phase registeredNCT06595615Health App Data Collection StudyAbbott Medical Devices · Cardiac DiseaseEnrolling by invitationABTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 2/Phase 3NCT06873035An Interventional Study of Infigratinib in Children With HypochondroplasiaQED Therapeutics, a BridgeBio company · HypochondroplasiaEnrolling by invitationBBIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 5, 2027Sponsor estimate | NCT06916728A Post Approval Multicenter 10 Year Follow-up Observational Trial of Marketed Product - MP01 vs. Surgical Standard of Care (SSOC) Used...Smith & Nephew, Inc. · Knee Injuries | SNNLead | No phase registered | Enrolling by invitation | Locked | Locked | Locked |
- Primary completion Feb 5, 2027Sponsor estimateNo phase registeredNCT06916728A Post Approval Multicenter 10 Year Follow-up Observational Trial of Marketed Product - MP01 vs. Surgical Standard of Care (SSOC) Used...Smith & Nephew, Inc. · Knee InjuriesEnrolling by invitationSNNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 17 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.